EU/3/18/2113

About

On 14 December 2018, orphan designation (EU/3/18/2113) was granted by the European Commission to MUCPharm Pty Ltd, United Kingdom, for bromelain for the treatment of pseudomyxoma peritonei.

The sponsorship was transferred to Mucpharm Europe Limited in February 2020.

Key facts

Active substance
Bromelain
Disease / condition
Treatment of pseudomyxoma peritonei
Date of first decision
14/12/2018
Outcome
Positive
EU designation number
EU/3/18/2113

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Mucpharm Europe Limited
2 Bella Vista Lodge
Rathfarnham
Dublin 14 D14 K2T9
Co. Dublin, Ireland
Tel: +35316710140
E-mail: david.morris@mucpharm.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating
Average
1 rating